Summary
The company was founded based on a license to the DUROS technology for specific therapeutic areas. DURECT subsequently acquired and developed additional advanced technologies to address a range of specific drug delivery challenges and enable the development of a broad product pipeline. The company's acquisition of IntraEar and Southern BioSystems further broadened its product offerings. Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
DURECT is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms: SABER Delivery System, ORADUR, TRANSDUR Delivery System, DURIN Biodegradable Implant, DUROS System and MICRODUR.
The company currently manufactures and sells finished products, ALZET and LACTEL. The company's lead proprietary candidate, ELADUR (TRANSDUR-Bupivacaine) is currently in Phase II clinical trials.
The company's total revenues increased at a CAGR of 32.1% during 2002-2006, from $7.2 million to $21.9 million. The company's biggest contributor to revenue growth during 2002-2006 was revenues from license, collaboration and others. Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company's adjusted five year financial data along with key ratios and market capitalization
|
Content
- Table Of Contents
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview And Key Facts
- Business Description
- History
- Locations And Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Geographic Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Ac Forecast Product Sales
- Competitors And Strategic Business Relationships
- Key Competitors
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- Swot Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery And Product Development
- Manufacturing
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List Of Key Employees
- Key Employee Biographies
- Financial And Operational Overview
- Financial And Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
- Table Of Figures
- Figure 1: Durect - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Durect - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Durect - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table Of Tables
- Table 1: Durect - Key Facts
- Table 2: Durect - Other Locations And Subsidiaries
- Table 3: Durect - Year-End Share Price And Market Capitalization, 2002-2006 ($)
- Table 4: Durect - Key Events Impacting Share Price Performance
- Table 5: Durect - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Durect - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
- Table 7: Durect - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Durect - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Durect - Revenue Breakdown By Division, 2002-2006 ($ Mn)
- Table 10: Durect - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 11: Durect - Marketed Products
- Table 12: Durect - In-House Pipeline Products
- Table 13: Durect - Collaboration Products
- Table 14: Durect - Forecast Sales, 2006-2010 ($ Mn)
- Table 15: Durect - Key Competitors
- Table 16: Durect - Key Clients
- Table 17: Durect - Key Shareholders
- Table 18: Durect - Swot Analysis Summary
- Table 19: Durect - Value Chain Analysis
- Table 20: Durect - Scorecard
- Table 21: Durect - Key Employees
- Table 22: Durect - Financial And Operational Overview
|
